Laboratoires Servier

Servier
Private
Industry Pharmaceutical
Founded (1954 (1954))
Founder Jacques Servier
Headquarters Suresnes, France
Products Pharmaceuticals
Revenue €3.9 billion (FY 2015)
Number of employees
 21,200
Website Official website
Footnotes / references
[1][2]

Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is a privately owned French pharmaceutical company that specialises in medication for cardiological and rheumatological conditions, as well as for diabetes and clinical depression.[3] The consolidated turnover for the 2015 financial year was €3.9 billion. Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company worldwide. It has branches in 140 countries, achieving 82% of its sales outside France.[3] The annual sales of its ACE inhibitor, Coversyl (perindopril), in 2006 and 2007 exceeded 1 billion US dollars, making it Servier's highest-selling product.

The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 21,200 employees worldwide. The company's production sites produced 853 million drug boxes in 2013.[3]

The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe.[4] Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[5]

Mediator, an amphetamine-based Servier drug originally developed for weight loss in people with diabetes but often prescribed off-label as a dieting aid, was withdrawn from the market after being linked to 500–2000 deaths in France.[6][7] Further investigations found that many previous safety alerts on that drug had been either missed or covered up, possibly through improper influence of the company.[7]

Product portfolio

Notable products:

Other products:

Collaborative research

As well as internal research and development activities, Servier undertakes publicly funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox.[9][10] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[11]

In addition to these, Servier engages in research and licensing collaborations across the pharmaceutical and biotechnology industry. These collaborations include:


References

  1. ↑ "Key figures". Servier. Retrieved 2015-02-03.
  2. ↑ "History". Servier. Retrieved 2015-02-03.
  3. 1 2 3 "SERVIER - Pharmaceutical company specialized in cardiology, diabetes, rheumatology, depression". Retrieved 2007-07-08.
  4. ↑ "Servier UK - Key figures". Archived from the original on 2007-07-08. Retrieved 2007-07-08.
  5. ↑ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 2008-09-16. Retrieved 2008-08-25.
  6. ↑ Article of the Figaro about Mediator
  7. 1 2 Un doute sur la «sécurité» du Mediator dès 1998 - Libération
  8. ↑ "SERVIER - product portfolio". Archived from the original on 2007-07-02. Retrieved 2007-07-08.
  9. ↑ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. Essential Concepts in Toxicogenomics. Methods in Molecular Biology. 460. pp. 221–238. ISBN 978-1-58829-638-2. PMID 18449490. doi:10.1007/978-1-60327-048-9_11.
  10. ↑ "InnoMed PredTox Member Organizations". Archived from the original on 2008-09-26. Retrieved 2008-08-25.
  11. ↑ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Retrieved 2008-08-25.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.